Volition(VNRX) Prnewswire·2025-03-21 12:30Core Insights - VolitionRx Limited has developed an automated Nu.Q® Cancer test that accurately detects 21 different types of cancers with high specificity and low false positive rates, potentially serving as a standalone pan-cancer test or in conjunction with other liquid biopsy technologies [1][4][5] - The company aims to disrupt the $20 billion annual market for liquid biopsy in the U.S. by providing early cancer detection solutions [2] - Volition is in discussions with large diagnostic and liquid biopsy companies to establish multiple licensing agreements, which may include milestone payments and ongoing revenue [3] Company Overview - Volition is a multi-national epigenetics company focused on advancing the science of epigenetics to improve early detection and monitoring of diseases, including cancer [6][7] - The company’s research and development activities are primarily based in Belgium, with additional facilities in the U.S. and London [8] Study Details - The study involved 229 cancer patients (including 70 early-stage patients) and 150 healthy subjects, demonstrating an overall AUC of 86% for detecting common fatal cancers such as lung, breast, prostate, colon, and liver cancers [4][5] - The Nu.Q® Cancer test is designed to be run on existing automated chemiluminescence platforms, making it accessible without the need for new hardware [4] Future Prospects - The company is focused on leveraging its existing technology to make Nu.Q® Cancer testing widely accessible through licensing and partnership arrangements [4] - There is potential for the Nu.Q® platform to be used not only for early cancer detection but also in the management of cancer patients, particularly in assessing treatment efficacy [5]